Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Event-Driven

<p>Japanese pharma firm <a href="https://www.smartkarma.com/entities/11747" target="_blank" data-smartkarma-citation="entities:11747:1">Takeda Pharmaceutical Co Ltd (4502 JP)</a> said it is officially considering making an offer for diversified rare-disease-focused <a href="https://www.smartkarma.com/entities/22142" target="_blank" data-smartkarma-citation="entities:22142:1">Shire PLC (SHP LN)</a> in what would probably be a merger of equals (both companies have recently traded around the $40 billion market cap level). We are maintaining our fair value estimates for both until we see evidence that discussions are advancing; an official offer is expected in April. While we see Takeda's shares as fairly valued, we’ve seen…</p>

Japanese pharma firm Takeda Pharmaceutical Co Ltd (4502 JP) said it is officially considering making an offer for diversified rare-disease-focused Shire PLC (SHP LN) in what would probably be a merger of equals (both companies have recently traded around the $40 billion market cap level). We are maintaining our fair value estimates for both until we see evidence that discussions are advancing; an official offer is expected in April. While we see Takeda's shares as fairly valued, we’ve seen…

Takeda Considers Swallowing Shire, a Somewhat Surprising Move That Could Make Strategic Sense